The vaccine manufacturer BioNTech has reached multi-million dollar settlements in the USA in a dispute over license fees.
The Mainz-based company will pay a total of 1.2 billion euros to the US health authority NIH and the University of Pennsylvania, as BioNTech announced upon request.
While the equivalent of around 759 million euros goes to the authorities, the university receives up to around 448 million euros. BioNTech had brought a corona vaccine onto the market with the US pharmaceutical giant Pfizer.
According to previous information from BioNTech, the dispute with the university was over “non-exclusive rights” to patent applications used in BioNTech and Pfizer’s Covid-19 vaccine. The dispute with the NIH – the acronym stands for National Institutes of Health – revolved around royalties and other related amounts.
According to BioNTech, the settlement with the NIH came about on December 20th, and that with the university on December 23rd. Both agreements do not constitute an admission of liability in relation to allegations made, BioNTech emphasized. A spokeswoman said these cases are different from litigation with competitors such as Moderna or CureVac. The university and the NIH authority are cooperation partners. Via NASDAQ, BioNTech shares temporarily rose by 0.36 percent to $114.18.
/chs/DP/nas
MAINZ (dpa-AFX)
Selected leverage products on BioNTech (ADRs)
With knock-outs, speculative investors can participate disproportionately in price movements. Simply select the desired leverage and we will show you suitable open-end products on BioNTech (ADRs)
The leverage must be between 2 and 20
Advertising
Image sources: Thomas Lohnes/Getty Images, Pavlo Gonchar/SOPA Images/LightRocket via Getty Images